Most immunotherapeutic approaches rely on αβ T lymphocytes, which, although highly specific, are limited by their dependence on MHC restriction, co-stimulatory signals, and recognition of tumor-associated antigens (TAAs) [37]. This evidence concerns the gene HLA-C and neoplasm.